Search
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. … Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain o...
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexInterleukin-7
go.drugbank.com/drugs/DB11997InvestigationalInterleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigational[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod]. … Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.
Ammonio methacrylate copolymer type A
go.drugbank.com/drugs/DB12031InvestigationalAmmonio methacrylate copolymer type a has been used in trials studying the treatment of GERD.
Synonyms: Ammonio methacrylate copolymer type AL-Baclofen
go.drugbank.com/drugs/DB12098InvestigationalL-Baclofen has been used in trials studying the treatment of Trigeminal Neuralgia.
Synonyms: L-BaclofenSotatercept
go.drugbank.com/drugs/DB12118ApprovedInvestigationalIt is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain.
Synonyms: (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-, (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-Bucillamine
go.drugbank.com/drugs/DB12160InvestigationalBucillamine has been used in trials studying the treatment and prevention of Gout and Rheumatoid Arthritis.
Categories: Compounds used in a research, industrial, or household settingTralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalWhile AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13). … [A242427] Tralokinumab is a fully human IgG4 monoclonal antibody targeted against IL-13.